INVO Fertility Patents Simplified Single-Chamber INVOcell Device, Protection Extends to 2040
INVO Fertility’s U.S. Patent No. 12,544,204 B2 for a simplified single-chamber INVOcell device became effective February 10, 2026, extending exclusive IP protection through 2040. The modification, based on clinical feedback, reinforces its proprietary intravaginal culture platform and underpins strategy across two INVO Centers and one IVF clinic.
1. Patent Issuance and Protection Period
INVO Fertility received U.S. Patent No. 12,544,204 B2 for the modified INVOcell® device effective February 10, 2026, securing intellectual property protection through 2040. This issuance establishes long-term exclusivity for the company’s intravaginal culture technology.
2. Simplified INVOcell Design
Years of real-world clinical use and practitioner feedback informed a streamlined INVOcell design featuring a single main chamber, eliminating the original microchamber. The simplified configuration is intended to reduce procedural complexity and enhance patient comfort and connectivity.
3. Strategic Implications for Growth
Extended IP coverage bolsters INVO Fertility’s expansion plan across its two operational INVO Centers and one in vitro fertilization clinic, while supporting device distribution to third-party clinics. The fortified patent portfolio may strengthen competitive positioning and investor confidence in the fertility services market.